Jade Biosciences, Inc. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Jade Biosciences, Inc. (JBIO) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 14.73 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-10
- Jade Biosciences, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-06-30 was 14.73M shares, a 49.66% increase year-over-year.
- Jade Biosciences, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 14.27M shares, a 57.30% decline year-over-year.
- Jade Biosciences, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-09-30 was 10.07M shares, a 24.06% decline year-over-year.
- Jade Biosciences, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-06-30 was 9.84M shares.
- Jade Biosciences, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 10.88M shares, a 346.91% increase from fiscal 2024.
- Jade Biosciences, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 2.43M shares, a 53.65% decline from fiscal 2023.
- Jade Biosciences, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 5.25M shares, a 26.90% increase from fiscal 2022.
- Jade Biosciences, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 4.14M shares, a 19.82% increase from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 0 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | 14.73M shares 10-Q · filed 2026-08-10 | 14.73M shares 10-Q · filed 2026-08-10 | ||||
| 2026-03-31 | 14.27M shares 10-Q · filed 2026-05-07 | |||||
| 2025-12-31 | 10.88M shares 10-K · filed 2026-03-06 | |||||
| 2025-09-30 | 10.07M shares 10-Q · filed 2025-11-14 | 10.07M shares 10-Q · filed 2025-11-14 | ||||
| 2025-06-30 | 9.84M shares 10-Q · filed 2026-08-10 | 9.84M shares 10-Q · filed 2026-08-10 | ||||
| 2025-03-31 | 33.41M shares 10-Q · filed 2026-05-07 | 2.33M shares 10-Q · filed 2025-04-25 | ||||
| 2024-12-31 | 15.53M shares 10-K · filed 2026-03-06 | 2.43M shares 10-K · filed 2025-03-27 | ||||
| 2024-09-30 | 13.26M shares 10-Q · filed 2025-11-14 | 3.71M shares 10-Q · filed 2024-11-12 | ||||
| 2024-06-30 | 13.14M shares 10-Q · filed 2025-08-13 | 5.63M shares 10-Q · filed 2024-08-12 | ||||
| 2024-03-31 | 6.48M shares 10-Q · filed 2025-04-25 | |||||
| 2023-12-31 | 5.25M shares 10-K · filed 2025-03-27 | |||||
| 2023-09-30 | 5.26M shares 10-Q · filed 2024-11-12 | |||||
| 2023-06-30 | 5.19M shares 10-Q · filed 2024-08-12 | |||||
| 2023-03-31 | 5.14M shares 10-Q · filed 2024-05-13 | |||||
| 2022-12-31 | 4.14M shares 10-K · filed 2024-03-25 | |||||
| 2022-09-30 | 4.18M shares 10-Q · filed 2023-11-13 | |||||
| 2022-06-30 | 3.96M shares 10-Q · filed 2023-08-14 | |||||
| 2022-03-31 | 3.70M shares 10-Q · filed 2023-05-15 | |||||
| 2021-12-31 | 3.45M shares 10-K · filed 2023-03-29 | |||||
| 2021-09-30 | 2.80M shares 10-Q · filed 2022-11-14 | |||||
| 2021-06-30 | 16.95M shares 10-Q · filed 2022-08-15 | |||||
| 2021-03-31 | 4.97M shares 10-Q · filed 2022-05-16 | |||||
| 2020-12-31 | 3.61M shares 10-K · filed 2022-03-30 | |||||
| 2020-09-30 | 3.60M shares 10-Q · filed 2021-11-15 | |||||
| 2020-06-30 | 1.37M shares 10-Q · filed 2021-08-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |